$54.06+0.15 (+0.28%)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $54.06. The stock is currently 18% below its 52-week high of $66.28, remaining 4.1% below its 200-day moving average. Technical signals show neutral RSI of 44 and bullish MACD crossover, explaining why BMRN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.
Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls
Some investors are considering whether BioMarin Pharmaceutical's current share price reflects its underlying value, or if the market may be overlooking certain factors. The stock last closed at US$54.53, with returns of a 1.7% decline over 7 days, 6.8% decline over 30 days, 8.3% decline year to date, 4.0% decline over 1 year, 44.9% decline over 3 years and 31.3% decline over 5 years. Recent coverage has focused on BioMarin's role in the biotechnology space and how sentiment around its...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.